PARSIPPANY, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2024.

"Our performance in the second quarter and fiscal first half of 2024 underscores the resiliency of our base business, as well as strong operational execution by our global team. Since our spinoff approximately two years ago, we've remained steadfast in delivering on our financial and strategic priorities, including standing embecta up as an independent company; maintaining stability within our core injection business; and investing in growth, most notably behind our insulin patch pump," said Devdatt (Dev) Kurdikar, Chief Executive Officer of embecta.

"During the second quarter, I am pleased to report that we made progress in each of these areas as evidenced by the transition of approximately 85 percent of our revenue to our own ERP system, shared service capability and distribution infrastructure; FDA’s continued review of our insulin patch pump 510(k) filing; and delivering financial results that exceeded our expectations. With the backdrop of our positive performance during the first half of the year, we are raising and tightening our fiscal 2024 outlook for our key financial metrics."

Second Quarter Fiscal Year 2024 Financial Highlights:

• Revenues of $287.2 million, up 3.6% on a reported basis; up 4.5% on a constant currency basis
  • U.S. revenues increased 0.8% on both a reported and constant currency basis
  • International revenues increased 6.8% on a reported basis, and 8.7% on a constant currency basis
• Gross profit and margin of $185.4 million and 64.6%, compared to $189.8 million and 68.5% in the prior year period
• Adjusted gross profit and margin of $185.8 million and 64.7%, compared to $190.1 million and 68.6% in the prior year period
• Operating income and margin of $39.2 million and 13.6%, compared to $55.6 million and 20.1% in the prior year period
• Adjusted operating income and margin of $74.9 million and 26.1%, compared to $84.9 million and 30.6% in the prior year period
• Net income and earnings per diluted share of $28.9 million and $0.50, compared to $14.0 million and $0.24 in the prior year period
• Adjusted net income and adjusted earnings per diluted share of $38.9 million and $0.67, compared to $43.3 million and $0.75 in the prior year period
• Adjusted EBITDA and margin of $90.8 million and 31.6%, compared to $96.7 million and 34.9% in the prior year period
• Announced a dividend of $0.15 per share

Six Months Ended March 31 2024 Financial Highlights:

• Revenues of $564.5 million, up 2.1% on a reported basis; up 2.2% on a constant currency basis
  • U.S. revenues increased 0.2% on both a reported and constant currency basis
  • International revenues increased 4.4% on both reported and constant currency basis
• Gross profit and margin of $371.3 million and 65.8%, compared to $378.6 million and 68.5% in the prior year period
• Adjusted gross profit and margin of $372.1 million and 65.9%, compared to $379.0 million and 68.6% in the prior year period
• Operating income and margin of $84.7 million and 15.0%, compared to $144.4 million and 26.1% in the prior year period
• Adjusted operating income and margin of $152.4 million and 27.0%, compared to $186.5 million and 33.7% in the prior year period
• Net income and earnings per diluted share of $49.0 million and $0.85, compared to $49.2 million and $0.85 in the prior year period
• Adjusted net income and adjusted earnings per diluted share of $74.2 million and $1.28, compared to $98.7 million and $1.71 in the prior year period
• Adjusted EBITDA and margin of $181.2 million and 32.1%, compared to $206.9 million and 37.4% in the prior year period

Strategic Highlights:

• Strengthen the base business
  • Sponsored the publication of a peer-reviewed paper authored by experts and opinion leaders in Postgraduate Medicine medical journal, entitled "Opportunities to overcome underutilization of enhanced insulin delivery technologies in people with type 2 diabetes: a narrative review"
• Separate and stand-up
  • Completed enterprise resource planning ("ERP") implementation comprising approximately eighty five percent of embecta's revenue base, including all three of its manufacturing plants; implemented new shared service capability and distribution infrastructure for U.S., Canada, EMEA and certain regions in Asia
  • Completed the transfer of the remaining Suzhou, China assets, including the manufacturing entity and related assets, from BD to embecta
  • Limited extension for amended Transition Services Agreement and Logistics Services Agreement granted by BD to support the Interim Business Continuity Processes until November 1, 2024
• Invest for growth
  • 510(k) premarket filing for the open-loop insulin delivery system with the U.S. Food and Drug Administration ("FDA") remains under review
  • Progressed the development of a type 2 closed loop insulin delivery system utilizing embecta’s proprietary patch pump system, which carries Breakthrough Device Designation from the FDA

Second Quarter Fiscal Year 2024 Results:

Revenues by geographic region are as follows:

The Company's revenues increased by $10.1 million, or 3.6%, to $287.2 million for the three months ended March 31, 2024 as compared to revenues of $277.1 million for the three months ended March 31, 2023. Changes in revenues are driven by the volume of goods that the Company sells, the prices it negotiates with customers and changes in foreign exchange rates. The increase in revenues was driven by $15.0 million of favorable changes in volume. This was partially offset by $2.5 million associated with the negative impact of foreign currency translation primarily due to the strengthening of the U.S. dollar, $1.4 million of unfavorable changes in price, and a $1.0 million decrease in contract manufacturing revenues related to sales of non-diabetes products to BD.

Six Months Ended March 31, 2024 Results:

Revenues by geographic region are as follows:

The Company's revenues increased by $11.7 million, or 2.1%, to $564.5 million for the six months ended March 31, 2024 as compared to revenues of $552.8 million for the six months ended March 31, 2023. The increase in revenues was driven by $13.0 million of favorable changes in volume and $2.0 million of favorable changes in price. This was partially offset by a $3.1 million decrease in contract manufacturing revenues related to sales of non-diabetes products to BD and $0.2 million associated with the negative impact of foreign currency translation primarily due to the strengthening of the U.S. dollar.

Fiscal Year 2024 Updated Financial Guidance:

For fiscal year 2024, the Company now expects:

(1) Previous guidance was issued on February 9, 2024.

We are unable to present a quantitative reconciliation of our expected adjusted gross margin, expected adjusted operating margin, expected adjusted earnings per diluted share, expected adjusted EBITDA and our expected adjusted EBITDA margin as we are unable to predict with reasonable certainty, and without unreasonable effort the impact and timing of any one-time items. The financial impact of these one-time items is uncertain and is dependent on various factors, including timing, and could be material to our Condensed Consolidated Statements of Income.

Balance sheet, Liquidity and Other Updates

As of March 31, 2024, the Company had approximately $306.5 million in cash and equivalents and restricted cash and $1.631 billion of debt principal outstanding, and no amount drawn on its $500 million Revolving Credit Facility.

The Company’s Board of Directors declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on June 14, 2024 to stockholders of record at the close of business on May 28, 2024.

Second Quarter Fiscal Year 2024 Earnings Conference Call:

Management will host a conference call at 8:00 a.m. Eastern Time (ET) on May 9, 2024 to discuss the results of the quarter, provide an update on its business, and host a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the Company’s website at investors.embecta.com.

A webcast replay of the call will be available beginning at 11:00 a.m. ET on May 9, 2024, via the embecta investor relations website and archived on the website for one year.

About Non-GAAP financial measures

In evaluating our operating performance, we supplement the reporting of our financial information determined under GAAP with certain non-GAAP financial measures including (i) earnings before interest, taxes, depreciation, and amortization (“EBITDA”), (ii) Adjusted EBITDA and Adjusted EBITDA Margin, (iii) Adjusted Gross Profit and Adjusted Gross Profit Margin, (iv) Constant Currency revenue growth, (v) Adjusted Operating Income and Adjusted Operating Income Margin, and (vi) Adjusted Net Income and Adjusted earnings per diluted share. These non-GAAP financial measures are indicators of our performance that are not required by, or presented in accordance with, GAAP. They are presented with the intent of providing greater transparency to financial information used by us in our financial analysis and operational decision-making. We believe that these non-GAAP measures provide meaningful information to assist investors, stockholders and other readers of our consolidated financial statements in making comparisons to our historical operating results and analyzing the underlying performance of our results of operations. However, the presentation of these measures has limitations as an analytical tool and should not be considered in isolation, or as a substitute for the company’s results as reported under GAAP. Because not all companies use identical calculations, the presentations of these non-GAAP measures may not be comparable to other similarly titled measures of other companies. The Company uses non-GAAP financial measures in its operational and financial decision making, and believes that it is useful to exclude certain items in order to focus on what it regards to be a meaningful alternative representation of the underlying operating performance of the business.

For the three and six month periods ended March 31, 2024 and 2023, the reconciliation of GAAP net income to EBITDA and adjusted EBITDA was as follows (unaudited, in millions):

For the three and six month periods ended March 31, 2024 and 2023, the reconciliations of (1) GAAP Gross Profit and Gross Margin to Adjusted Gross Profit and Adjusted Gross Margin, (2) GAAP Operating Income and Operating Margin to Adjusted Operating Income and Adjusted Operating Income Margin and (3) GAAP Net Income to Adjusted Net Income and calculations of GAAP Net Income per Diluted share and Adjusted Net Income per Diluted share are as follows (unaudited in millions, except per share amounts):

Each reporting period, we face currency exposure that arises from translating the results of our worldwide operations to the U.S. dollar at exchange rates that fluctuate from the beginning of such period. A stronger U.S. dollar, compared to the prior-year period, resulted in an unfavorable foreign currency translation impact to our revenues as compared to the prior-year period. We evaluate our results of operations on both a reported and a Constant Currency basis, which excludes the impact of fluctuations in foreign currency exchange rates by comparing results between periods as if exchange rates had remained constant period-over-period. As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a Constant Currency basis in addition to reported results helps improve investors’ ability to understand our operating results and evaluate our performance in comparison to prior periods. We calculate Constant Currency percentages by converting our current-period local currency financial results using the prior-period foreign currency exchange rates and comparing these adjusted amounts to our current-period results. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP. Results on a Constant Currency basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.

For the three and six month periods ended March 31, 2024 and 2023, the reconciliation of revenue growth to Constant Currency was as follows:

About Embecta

embecta is a global diabetes care company that is leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.

Safe Harbor Statement Regarding Forward-Looking Statements

This press release contains express or implied "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements concern our current expectations regarding our future results from operations, performance, financial condition, goals, strategies, plans, achievements, and anticipated product clearances, approvals and launches. These forward-looking statements are subject to various known and unknown risks, uncertainties and other factors, and you should not rely upon them except as statements of our present intentions and of our present expectations, which may or may not occur. When we use words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “pursue,” “will” or similar expressions, we are making forward-looking statements. For example, embecta is using forward-looking statements when it discusses its fiscal 2024 financial guidance, standing embecta up as independent company, maintaining stability with its core injection business and investing in growth, including with respect to working with the FDA to obtain clearance for new and anticipated products and launches and advancing the development of its closed loop insulin delivery system. Although we believe that our forward-looking statements are based on reasonable assumptions, our expected results may not be achieved, and actual results may differ materially from our expectations. In addition, important factors that could cause actual results to differ from expectations include, among others: (i) competitive factors that could adversely affect embecta’s operations; (ii) any inability to replace the services provided by BD under the Transition Services Agreement, the Logistics Services Agreement and other transaction documents; (iii) any failure by BD to perform its obligations under the various separation agreements entered into in connection with the separation and distribution; (iv) any events that adversely affect the sale or profitability of embecta’s products or the revenues delivered from sales to its customers; (v) increases in operating costs, including fluctuations in the cost and availability of raw materials or components used in its products, the ability to maintain favorable supplier arrangements and relationships, and the potential adverse effects of any disruption in the availability of such items; (vi) changes in reimbursement practices of governments or private payers or other cost containment measures; (vii) the adverse financial impact resulting from unfavorable changes in foreign currency exchange rates, as well as regional, national and foreign economic factors, including inflation, deflation, and fluctuations in interest rates; (viii) the impact of changes in U.S. federal laws and policy that could affect fiscal and tax policies, healthcare and international trade, including import and export regulation and international trade agreements; (ix) any new pandemic, such as the COVID-19 pandemic, or any geopolitical instability, including disruptions in its operations and supply chains; (x) new or changing laws and regulations, or changes in enforcement practices, including laws relating to healthcare, environmental protection, trade, monetary and fiscal policies, taxation and licensing and regulatory requirements for products; (xi) the expected benefits of the separation from BD; (xii) risks associated with embecta’s indebtedness; (xiii) the risk that ongoing dis-synergy costs, costs of restructuring and other costs incurred in connection with the separation from BD will exceed our estimates of these costs; (xiv) the risk that it will be more difficult than expected to effect embecta’s full separation from BD; (xv) risks associated with not completing strategic collaborative partnerships and acquisitions for innovative technologies, complementary product lines, and new markets; (xvi) embecta’s ability to obtain clearance from the FDA of any product; (xvii) its ability to market and sell such products successfully; (xviii) its ability to anticipate the needs of people with diabetes; (xix) its ability to successfully complete clinical trials, obtain regulatory clearance and obtain approvals for its products; (xx) its ability to manufacture such products in a cost-effective manner, obtain appropriate intellectual property protection for such products, gain and maintain market acceptance of such products, secure distribution channels, and obtain access, coverage and reimbursement for such products; (xxi) future business decisions made by embecta and its competitors; and (xxii) the other risks described in our periodic reports filed with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K, as further updated by our Quarterly Reports on Form 10-Q we have filed or will file hereafter. Except as required by law, we undertake no obligation to update any forward-looking statements appearing in this release.

CONTACTS 
 
Investors:
Pravesh Khandelwal
VP, Head of Investor Relations
551-264-6547
Contact IR

Media:
Christian Glazar
Sr. Director, Corporate Communications
908-821-6922
Contact Media Relations